Dr. Thohan to Lead Preclinical Programs Toward Phase I Clinical Trials
San Diego, CA — May 27, 2025 — Global Cancer Technology (GCT) is pleased to
announce the appointment of Dr. Sanjeev Thohan as Chief Development Officer. A
seasoned industry leader, Dr. Thohan brings decades of experience guiding
biopharmaceutical companies through IND-enabling studies and early-phase clinical
development.
“I’m honored to join GCT as Chief Development Officer,” said Dr. Thohan. “Our priority
is advancing GCT-007—a small molecule PI3K inhibitor—through the IND-enabling
process and into the clinic.”
GCT CEO John Clark added, “We’ve seen highly encouraging preclinical results,
especially when GCT-007 is combined with checkpoint inhibitors. Dr. Thohan’s proven
ability to move molecules through preclinical development—42 compounds to date—
positions us for a strong entry into our Phase I glioblastoma trial.”
Dr. Karen Newell Rogers, GCT’s Chief Scientific Officer, noted, “The preclinical
performance of GCT-007 has exceeded expectations. We’re thrilled to welcome Dr.
Thohan and his expertise as we move closer to clinical trials.”
About Global Cancer Technology
Global Cancer Technology is a preclinical-stage biopharmaceutical company focused on
advancing novel therapeutics for oncology. The company is currently raising investment
capital to support its planned Phase I clinical trial.
Learn more at:
www.globalcancertechnology.com
________________________________________________________________________
This press release may contain forward-looking statements as defined by Section 27A of
the U.S. Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements involve risks and uncertainties as outlined in the Company’s
shareholder communications. There is no guarantee that any product will receive FDA
approval or achieve commercial success.
